655 related articles for article (PubMed ID: 26449250)
1. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
[TBL] [Abstract][Full Text] [Related]
2. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
[TBL] [Abstract][Full Text] [Related]
4. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
[TBL] [Abstract][Full Text] [Related]
6. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
7. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
[TBL] [Abstract][Full Text] [Related]
8. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
9. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
[TBL] [Abstract][Full Text] [Related]
10. Continuous daily sunitinib for recurrent glioblastoma.
Kreisl TN; Smith P; Sul J; Salgado C; Iwamoto FM; Shih JH; Fine HA
J Neurooncol; 2013 Jan; 111(1):41-8. PubMed ID: 23086433
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
[TBL] [Abstract][Full Text] [Related]
12. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice.
Wang Y; Wernersbach I; Strehle J; Li S; Appel D; Klein M; Ritter K; Hummel R; Tegeder I; Schäfer MKE
Brain Behav Immun; 2022 Nov; 106():49-66. PubMed ID: 35933030
[TBL] [Abstract][Full Text] [Related]
13. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
Brown NF; Williams M; Arkenau HT; Fleming RA; Tolson J; Yan L; Zhang J; Singh R; Auger KR; Lenox L; Cox D; Lewis Y; Plisson C; Searle G; Saleem A; Blagden S; Mulholland P
Neuro Oncol; 2018 Nov; 20(12):1634-1642. PubMed ID: 29788497
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
[TBL] [Abstract][Full Text] [Related]
16. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.
Sosna J; Philipp S; Albay R; Reyes-Ruiz JM; Baglietto-Vargas D; LaFerla FM; Glabe CG
Mol Neurodegener; 2018 Mar; 13(1):11. PubMed ID: 29490706
[TBL] [Abstract][Full Text] [Related]
17. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M
J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703
[TBL] [Abstract][Full Text] [Related]
18. CSF1R inhibitor PLX3397 depletes microglia in Mongolian gerbil Meriones unguiculatus, but not in syrian hamster Mesocricetus auratus.
Sato RY; Zhang Y; Kotake KT; Onishi H; Ito S; Norimoto H; Zhou Z
J Pharmacol Sci; 2024 Jun; 155(2):29-34. PubMed ID: 38677783
[TBL] [Abstract][Full Text] [Related]
19. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
